


PHARMACEUTICAL 2023



Longboard Pharmaceuticals Inc. Rank 147 of 446







PHARMACEUTICAL 2023



Longboard Pharmaceuticals Inc. Rank 147 of 446

The relative strengths and weaknesses of Longboard Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Longboard Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 104% points. The greatest weakness of Longboard Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is 157%, being 114% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	69,838
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,764
Liabilities, Non-Current	0
Other Assets	769
Other Compr. Net Income	-528
Other Expenses	0
Other Liabilities	0
Other Net Income	853
Other Revenues	0
Property and Equipment	9.0
Research and Development	34,638
Selling, General and Administrative Expense	10,160

Output Variable	Value in 1000 USD
Assets	70,616
Liabilities	8,764
Expenses	44,798
Revenues	0
Stockholders Equity	61,852
Net Income	-43,945
Comprehensive Net Income	-44,209
Economic Capital Ratio	157%

